Daniel Moreno

Daniel Moreno, CPA, is a seasoned finance professional with extensive experience in financial reporting and analysis, currently serving as the GL Manager for Innovative Medicines, Biomedical Research, and Product Costing at Novartis since July 2020. Responsibilities include leading the Customer & Technology Solutions reporting team, overseeing intercompany reconciliations, and managing order-to-cash activities. Previously, Daniel held positions at UBS as Director of Group External Reporting, at zeb consulting as Senior Consultant in Finance & Risk, and at PwC as Audit Manager, where oversight included regulatory and financial audits primarily in the banking and asset management sectors. Daniel holds a Master of Arts in Accounting and Finance and is a Swiss Certified Public Accountant.